30results about How to "Good immunosuppressive activity" patented technology

A compound having immunosuppressive activity with low toxicity or a pharmacological salt thereof. The compound has a general formula (I) shown below or a pharmacologically acceptable salt thereof, or a pharmacologically acceptable prodrug thereof

A pharmaceutical composition useful as a preventive or therapeutic agent for immune-related diseases. The pharmaceutical composition includes at least HMG-COA reductase inhibitor and at least one amino alcohol compound having the following formula (I), a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof

wherein R¹ and R² each represents hydrogen; R³ represents lower alkyl or hydroxymethyl; R⁴ represents hydrogen, alkyl, alkoxy or halogen; R⁵ represents hydrogen, halogeno, cyclohexyl or phenyl; X represents vinylene (CH═CH), oxygen, sulfur or methylated nitrogen; Y represents a single bond, oxygen, sulfur or carbonyl; Z represents a single bond or C₁-C₈ alkylene; n is 2 or 3.

Compounds of formula (I) which exhibit excellent immune suppression activity, pharmacologically acceptable salts thereof, esters thereof or other derivatives:

wherein R¹ and R² are a hydrogen atom, an amino protecting group; R³ is a hydrogen atom, a hydroxy protecting group; R⁴ is a lower alkyl group; n is an integer from 1 to 6; X is an ethylene group; Y is a C₁-C₁₀ alkylene group, a C₁-C₁₀ alkylene group substituted with 1 to 3 substituents selected from substituent group a and b; R⁵ is an aryl group; R⁶ and R⁷ are a hydrogen atom, a group selected from substituent group a; with the proviso when R⁵ is a hydrogen atom, Y is not a single bond or a straight chain C₁-C₁₀ alkylene group.

Antibody conjugates of immune-modulatory compounds and pharmaceutical compositions for use in the treatment of disease, such as fibrotic diseases, autoimmune, or autoinflammatory diseases, are disclosed herein. The disclosed conjugates are useful, among other things, in treating fibrotic diseases, autoimmune diseases, or autoinflammatory diseases, such as by modulating TGFβR1, TGFβR2, TNKS, TNIK, or mTOR.

The invention relates to cortex phellodendri polysaccharide extract and a preparation method and medical application thereof. The content of cortex phellodendri polysaccharide in the extract is counted by glucose, and the content of the polysaccharide accounts for above 65% of the cortex phellodendri extract in percentage by weight. Found by a large number of pharmacological experiments, the cortex phellodendri general polysaccharide extract has notable immunosuppressive activity, can be prepared into immunosuppressive medicaments or used as a medicinal material for preparing other immunosuppressive medicaments, and can be used for treating various immunoreaction-related diseases, including nephritis, pharyngitis, pneumonitis, upper respiratory tract infection, hepatitis, enteritis, gynecologic inflammation, rheumatoid arthritis, diabetes and other immune-related diseases.

The invention discloses asymmetric cyclobutane derivatives (synthetic derivatives G of rabdosia scoparia lactones), which are named as scopariusicide derivatives, a pharmaceutical composition taking the asymmetric cyclobutane derivatives as the active component, a preparation method of asymmetric cyclobutane derivatives, and an application of asymmetric cyclobutane derivatives in preparation of immuno-suppressive drugs. According to the preparation, scopariusicides, which is derived from pharmaceutical plants, is taken as the template; a precursor compound ent-clerodane diterpene A is taken as the initial raw material, a series of artificial analogues are obtained through six steps of chemical synthesis; the basic structure of the derivatives has a characteristic that ent-clerodane hetero-diterpene has an asymmetric cyclobutane segment, the side chain and aromatic ring of the derivatives may have different substituents, and thus there are many kinds of derivatives. The compounds are synthesized for the first time, the synthesis route is novel, and the derivatives have potential bioactivity, can be used as the lead compounds of immuno-suppressive drugs, and have a very important research value and application prospect.

The present invention relates to a method for selecting high-efficacy mesenchymal stem cells for use in treating an immune disease, the method comprising a step of measuring a level of a particular immunosuppressive biomarker in mesenchymal stem cells in which the expression or activity of suppressor of cytokine signaling (SOCS) is downregulated, high-efficacy mesenchymal stem cells selected by the method, and a method for treating an immune disease by using the high-efficacy mesenchymal stem cells. Providing a method useful for acquiring functionally excellent mesenchymal stem cells having anability to control immune reactions for clinical treatment of various immune diseases including graft-versus-host diseases and autoimmune diseases, the present invention can find useful applicationsin the therapy of immune diseases.

According to the present invention, a Phomopsis asparagi DHS-48 fermentation product is further separated and purified to obtain a compound having a novel structure, and the evaluation on the cytotoxicity and the immunosuppressive activity of the compound proves that the compound has low cytotoxicity and significant immunosuppressive activity on mouse splenocytes. The study on the mechanism of action shows that the compound is a potential immunosuppressor capable of inhibiting the dephosphorylation of the intracellular phosphorylated NFAT protein, and can be used for preparing immunosuppressive drugs aiming at organ transplantation and autoimmune diseases.

The present disclosure relates to cellular therapy products comprising mesenchymal lineage precursor or stem cells and potency assay for these products. The present disclosure also relates to methods for treatment of immune or inflammatory disorders, and treatment or prevention of graft versus host disease (GVHD), or one or more symptoms associated with GVHD, by administration of mesenchymal lineage precursor or stem cells.

The invention discloses a four-membered ring-containing hetero-diterpenoid compound, and relates to the technical field of medicines and a preparation method and application thereof, the hetero-diterpenoid compound is novel in structure, has an inhibition effect on T and B lymphocyte proliferation, has selectivity on the inhibition effect on T cells, and can be widely applied to preparation of immunosuppressive medicines. The preparation method of the hetero-diterpenoid compound is easy to operate and mild in condition, and the hetero-diterpenoid compound can be rapidly and efficiently obtained. The invention also discloses a pharmaceutical composition which comprises the hetero-diterpenoid compound and pharmaceutically acceptable auxiliary materials. The compound has good immunosuppressive activity and can be used as an immunosuppressive agent.

The invention discloses tuber melanosporum, cordyceps and rhizoma polygonati granules and a preparation method thereof, and relates to the technical field of health care products. The raw materials ofthe tuber melanosporum, cordyceps and rhizoma polygonati granules comprise main materials and auxiliary materials, wherein the main materials include the following ingredients in parts by weight: 3-6parts of tuber melanosporum extracts, 3-6 parts of cordyceps powders, 12-16 parts of stichopus japonicas extracts, 12-16 parts of cervus nippon penis et testis cervi extracts, 7-10 parts of Maca powders, 10-15 parts of radix morindae officinalis extracts, 10-15 parts of rhizoma polygonati extracts, 10-15 parts of prepared radix rehmanniae extracts and 18-25 parts of glycyrrhizae radix extracts. In the tuber melanosporum, cordyceps and rhizoma polygonati granules, the glycyrrhizae radix is put in an important position, rhizoma polygonati is taken as an auxiliary material, the efficacy of warming the middle and benefiting qi of the rhizoma polygonati is taken, the stichopus japonicas is assisted to nourish the blood, nourish yin and replenish yin fluid, then, ingredients, including the tuber melanosporum extracts, the cordyceps powders, the cervus nippon penis et testis cervi extracts, the Maca powders, the radix morindae officinalis extracts the prepared radix rehmanniae extracts and the like, are added to nourish yin, supplement the kidney and enhance a human body autoimmunity function, the internal environment of the human body is maintained, physical power is accelerated to recover, the own anti-fatigue ability of the human body is improved, and the tuber melanosporum, cordyceps and rhizoma polygonati granules can be used for health care and body nourishment.

The present invention relates to a monoclonal antibody having excellent immunosuppressive activity or an antigen binding fragment thereof. More specifically, the present invention relates to a monoclonal antibody or an antigen binding fragment thereof, which binds to a peptide consisting an amino acid sequence represented by SSVLYGGPPSAA (SEQ ID NO: 1) or a conjugate of the peptide and a pharmaceutically acceptable carrier, the monoclonal antibody or an antigen binding fragment thereof having a higher binding affinity for core histone than for histone H1.

The invention relates to the technical field of medical microbial chemistry, and particularly discloses a furan ring derivative separated from a liquid fermentation product of an Ophiocordyceps xuefengensis strain and an application of the furan ring derivative in preparation of an immunosuppressive drug, more particularly an application of the furan ring derivative in preparation of a drug with remarkable inhibitory activity on T cell proliferation. According to the invention, the immunosuppressive effect of the furan ring derivative is better than that of an immunosuppressive agent cyclosporin A which is widely used clinically, and the furan ring derivative is an efficient immunosuppressive agent and can be used for preparing immunosuppressive drugs for organ transplantation and autoimmune diseases.

The invention discloses a bis-(10-deoxydihydroartemisinin)-phloroglucinol derivative, the structural formula of the bis-(10-deoxydihydroartemisinin)-phloroglucinol derivative is shown in the specification, and the invention also provides a preparation method of the bis-(10-deoxydihydroartemisinin)-phloroglucinol derivative shown in the general formula (I). The invention also provides an application of the bis-(10-deoxydihydroartemisinin)-phloroglucinol derivative of the general formula (I) in preparation of a medicine for treating autoimmune diseases. The compounds provided by the invention are novel compounds for treating autoimmune diseases, have low cytotoxicity, can significantly inhibit immune cell proliferation, effectively inhibit ear swelling induced by 2, 4-dinitrofluorobenzene and plantar swelling induced by sheep erythrocytes on an ear swelling model and a plantar swelling model of delayed hypersensitivity, and can be used for treating autoimmune diseases. The compound shows a good dose-effect relationship, and has a very wide application prospect as a medicine for treating autoimmune diseases.